AU · rank #14 · 2026-07-23
DSFIR
AMSTERDAM · EUR · $24.00B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.562 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.03 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 4 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $85.54 | +0.5% |
| Momentum acceleration 3-month minus 12-month momentum. | +37.46% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.05 |
| Gross margin TTM | +39.1% |
| 52w high | $87.68 |
| Market cap (USD) | $24.00B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
DSM-Firmenich AG is a specialty chemicals company focused on consumer ingredients across nutrition, health, and beauty, currently divesting its lower-margin Animal Nutrition & Health business.
Rationale
The 54% analyst upside and strong upward EPS revisions are supported by structural margin expansion from the ANH divestment, active €540M share buybacks, and robust demand in Perfumery & Beauty.
Material risks
- 1Imminent earnings risk from the upcoming July 30, 2026 report, where rising Middle East freight and energy costs may pressure EBITDA margins.
- 2Significant negative foreign exchange headwinds eroding reported sales growth and complexity in finalizing the €2.2 billion ANH divestment.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.